Sessions

How to Market my Biotech to Investors: Lessons Learned from Successful Investment and Funding Rounds
Workforce of the Future: Talent, Change Management and Enabling Future Development
Delivering Projects and Managing Timelines in the Variable, Continuously Changing Environment Of Cell and Gene Therapy
Patient and Payer Challenges: Enabling Access to Patients through Market Access, Pricing and Patient-Led Discussion
Moving the Industry Towards Automated Systems for Scale-up Success
Tech Review: New Platforms and Closed-Systems to Enable Commercial Success
Working With a CDMO is not Just an Outsourcing Contract but a Partnership: Learnings from Successful Biotech/CDMO Partnerships
Overcoming Challenges and Setting Up for Success on the Path to Commercialisation
Overcoming Challenges and Setting Up for Success on the Path to Commercialisation

How to Market my Biotech to Investors: Lessons Learned from Successful Investment and Funding Rounds

28 Jan 2022
09:00

09:00 Chairperson’s Opening
Bryan Poltilove, Operational Partner, Broadoak Capital Partners

09:05 Accelerating Cures Translating stem cell discoveries into therapies

  • Early stage funds to de-risk and commercialize stem cell technologies
  • What investors look for

Amritha Jaishankar, Executive Director, Maryland Stem Cell Research Fund (MSCRF)

09:20 Incubators, Accelerators and “Hackathons” – What Investors Need to Know

  • Defining terms: Incubators, Accelerators, and Hackathons
  • What is the investor value of Incubators, Accelerators, and Hackathons?
  • How to differentiate between Incubators and Accelerators that add value, or just collect checks , equity, and PR.

Louis Walcer, Director, The Kevin M. McGovern Family Center for Venture Development in Life Sciences, Cornell University

09:35 A Startup Owners Manual: Rejection, Persistence, and Success in Financing

  • Investor dating: how to find the right partner and what they are looking for
  • Building for a big vision and creating positive signaling along the way
  • Practice makes perfect: being persistent and dealing with rejection

Brian Feth, Co-Founder and Chief Executive Officer, Xcell Biosciences

09:50 Taking A Drug Product beyond Phase 2 With Multiple Investment Rounds

  • An early IPO, pros and cons
  • Handling expectations

Mathias Svahn, Chief Executive Officer and Co-Founder, NextCell Pharma

10:05  Speaker Q&A and Panel Discussion

Joined by all session speakers

Speakers

Bryan Poltilove
Operational Partner
Broadoak Capital Partners
Amritha Jaishankar
Executive Director
Maryland Stem Cell Research Fund
Louis Walcer
Director, The Kevin M. McGovern Family Center for Venture Development in the Life Sciences
Cornell University
Brian Feth
Co-Founder and Chief Executive Officer
Xcellbio
Mathias Svahn
Chief Executive Officer
NextCell Pharma